search

Electrocore LLC (ECOR)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
electroCore seeks FDA clearance for Quell in chronic CIPN
Oct 28, 2026

electroCore seeks FDA clearance for Quell in chronic CIPN

electroCore (NASDAQ: ECOR) has submitted a 510(k) notification to the FDA for clearance of its Quell device to treat chronic chemotherapy-induced peripheral neuropathy, based on two studies with 168 participants. The company aims to expand into cancer supportive care with this non-invasive neurostimulation product. While preliminary data showed an 11.6% improvement in the active group compared to 8.7% for sham, the submission does not guarantee marketing clearance, and a decision date has not been announced.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish